Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1674203 | 1.00 | CA1 (0.44) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL2290678 | 1.00 | CA1 (0.44) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL23292518 | 1.00 | CA1 (0.44) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL19970649 | 0.96 | CA1 (0.45) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL1561831 | 0.96 | CA1 (0.45) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL2562479 | 0.96 | CA1 (0.45) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL3751041 | 0.96 | CA1 (0.45) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL1263178 | 0.96 | CA1 (0.45) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL4833427 | 0.92 | CA1 (0.42) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL5999732 | 0.92 | CA1 (0.42) | CA1CA2CA7CA9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020111481-A1 | Processes for the preparation of alphaGal(1-4)betaGal(1-4)Glc-OR trisaccharides | SYNSORB BIOTECH, INC. (CA) | 2002-08-15 | — | — | US | claimed |
| WO-2002048163-A2 | PROCESSES FOR THE PREPARATION OF αGAL(1→4)βGAL(1→4)GLC-OR TRISACCHARIDES | SYNSORB BIOTECH, INC. (CA) | 2002-06-20 | — | — | WO | claimed |
| EP-3814364-A1 | IMPROVED PROCESS FOR PREPARATION OF 2,3,4,6-TETRA-O-BENZYL-D-GALACTOSE | Aarti Industries Limited (IN) | 2021-05-05 | — | — | EP | disclosed |
| EP-3814364-A1 | IMPROVED PROCESS FOR PREPARATION OF 2,3,4,6-TETRA-O-BENZYL-D-GALACTOSE | Aarti Industries Limited (IN) | 2021-05-05 | — | — | EP | disclosed |
| EP-3814364-A1 | IMPROVED PROCESS FOR PREPARATION OF 2,3,4,6-TETRA-O-BENZYL-D-GALACTOSE | Aarti Industries Limited (IN) | 2021-05-05 | — | — | EP | disclosed |
| CN-112262148-A | Improved process for the preparation of 2,3,4, 6-tetra-O-benzyl-D-galactose | 阿尔第实业有限公司 | 2021-01-22 | — | — | CN | disclosed |
| CN-112262148-A | Improved process for the preparation of 2,3,4, 6-tetra-O-benzyl-D-galactose | 阿尔第实业有限公司 | 2021-01-22 | — | — | CN | disclosed |
| CN-112262148-A | Improved process for the preparation of 2,3,4, 6-tetra-O-benzyl-D-galactose | 阿尔第实业有限公司 | 2021-01-22 | — | — | CN | disclosed |
| US-10765648-B2 | iNKT cell modulators and methods of using the same | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2020-09-08 | — | — | US | disclosed |
| EP-2785683-B1 | INKT CELL MODULATORS AND METHODS OF USING THE SAME | LUDWIG INST FOR CANCER RES LTD (CH) | 2020-02-05 | — | — | EP | disclosed |
| US-10314796-B2 | iNKT cell modulators and methods of using the same | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2019-06-11 | — | — | US | disclosed |
| EP-0829104-A1 | HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1998-03-18 | — | — | EP | disclosed |
| US-5622936-A | COMPLEX OF SUGAR WITH A PHOSPHORUS AMIDE | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS (DE) | 1997-04-22 | — | — | US | disclosed |
| EP-0729648-A4 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LTD (AU) | 1997-01-02 | — | — | EP | disclosed |
| WO-1996035239-A1 | HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-11-07 | — | — | WO | disclosed |
| EP-0729648-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-09-04 | — | — | EP | disclosed |
| WO-1995012219-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1995-05-04 | — | — | WO | disclosed |
| EP-0369182-B1 | Antitumour saccharide conjugates | DEUTSCHES KREBSFORSCH (DE) | 1995-03-29 | — | — | EP | disclosed |
| EP-0369182-A1 | Antitumour saccharide conjugates | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 1990-05-23 | — | — | EP | disclosed |
| WO-1990004597-A1 | TUMOR-INHIBITING SACCHARIDE CONJUGATES | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 1990-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10765648-B2 | iNKT cell modulators and methods of using the same | PBK, NFATC1, UGCG | CA1 2716/4885CA2 3423/4885CA7 3781/4885 |
| US-20020111481-A1 | Processes for the preparation of alphaGal(1-4)betaGal(1-4)Glc-OR trisaccharides | B3GAT3, B4GALT1, GALE | CA1 795/4885CA2 2413/4885CA7 548/4885 |
| US-10314796-B2 | iNKT cell modulators and methods of using the same | PBK, NFATC1, UGCG | CA1 2716/4885CA2 3423/4885CA7 3781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.